Patterns of opioid dose escalation in patients with chronic kidney disease initiated on opioids for the treatment of non-cancer pain.
No Thumbnail Available
Authors
Zin C.S.
Lando S.
GonzalezOrtiz A.
Mahalingasivam V.
Mostafaei S.
Ahmad W.R.
Shah M.M.A.
Wettermark B.
Carrero, J. J.
Contact
Check for full-text access
Issue Date
2026
Type
Article
Language
Keywords
Alternative Title
Abstract
Background Pain management in chronic kidney disease (CKD) is challenging due to altered drug metabolism, impaired excretion, and higher opioid toxicity risk. Despite this, opioids are commonly prescribed, yet real-world data on dose escalation in CKD remain limited. Objective To investigate patterns and timing of opioid dose escalation to >=50 and >=90 MME/day among new opioid users across kidney function levels. Methods This population-based cohort study used data from the Stockholm Creatinine Measurements (SCREAM) project linking diagnoses, prescriptions, and laboratory records. Adult new opioid users (no prior opioid in 12 months) from 2012-2021 were categorized by baseline eGFR (>=60, 30-59, <sup>2).</sup> Opioids were identified using ATC codes, and daily doses (MME/day) were calculated based on strength, quantity, and equianalgesic ratios. Fine-Gray competing-risks regression assessed time to dose escalation (>=50 and >=90 MME/day), accounting for death as a competing event. Results Of 81,987 adult new opioid users, 5,987 (7.3%) escalated to >=50 MME/day comprising 7.4%, 6.8%, and 8.1% of patients with eGFR>=60, 30-59, and Opioids were identified using ATC codes, and daily doses (MME/day) were calculated based on strength, quantity, and equianalgesic ratios. Fine-Gray competing-risks regression assessed time to dose escalation (>=50 and >=90 MME/day), accounting for death as a competing event. Results Of 81,987 adult new opioid users, 5,987 (7.3%) escalated to >=50 MME/day comprising 7.4%, 6.8%, and 8.1% of patients with eGFR>=60, 30-59, and <sup>2,</sup> respectively. For >=90 MME/day, 2,067 (2.5%) escalated, 2.5%, 2.3%, and 2.9% across the same eGFR categories. Competing risks regression showed significantly lower risks of escalation among patients with reduced eGFR levels. For >=50 MME/day, the sub distribution hazard ratios (SHRs) were 0.67 (95% CI: 0.56-0.81, p respectively. For >=90 MME/day, 2,067 (2.5%) escalated, 2.5%, 2.3%, and 2.9% across the same eGFR categories. Competing risks regression showed significantly lower risks of escalation among patients with reduced eGFR levels. For >=50 MME/day, the sub distribution hazard ratios (SHRs) were 0.67 (95% CI: 0.56-0.81, p=90 MME/day, SHRs were 0.57 (95% CI: 0.43-0.75, p<0.001) and 0.31(95% CI: 0.15-0.65, p=0.002), respectively. Most escalation occurred within six months, with minimal increase thereafter. Conclusion Opioid dose escalation occurred across all eGFR levels, underscoring the need for cautious, individualized prescribing and close monitoring, especially in patients with reduced kidney function. Copyright © 2026 Zin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Description
Citation
Publisher
License
Journal
PLOS ONE
Volume
21